Thrombocytopenia-associated multiple-organ failure (TAMOF): recognition and management

BMJ Case Rep. 2018 Aug 27:2018:bcr2018225594. doi: 10.1136/bcr-2018-225594.

Abstract

Thrombocytopenia-associated multiple-organ failure (TAMOF) is an increasingly fatal phenomenon that may be associated with sepsis. TAMOF results from immune dysregulation and impaired activity of A Disintegrin And Metalloproteinase with ThromboSpondin type 1 motif, member 13. Early recognition of this premorbid condition and specific management results in a significantly improved outcome. Herein, we report the presentation and management of a 2-year-old child with TAMOF who was successfully treated with plasma exchange and recovered without long-term sequelae.

Keywords: acute renal failure; mechanical ventilation; paediatric intensive care.

Publication types

  • Case Reports

MeSH terms

  • ADAMTS13 Protein / drug effects*
  • Child, Preschool
  • Critical Illness
  • Fluid Therapy
  • Humans
  • Male
  • Multiple Organ Failure / blood
  • Multiple Organ Failure / physiopathology
  • Multiple Organ Failure / therapy*
  • Plasma Exchange / methods*
  • Sepsis / blood
  • Sepsis / physiopathology
  • Sepsis / therapy*
  • Thrombocytopenia / blood
  • Thrombocytopenia / complications
  • Thrombocytopenia / physiopathology
  • Thrombocytopenia / therapy*
  • Time Factors
  • Treatment Outcome
  • Vasoconstrictor Agents / administration & dosage*

Substances

  • Vasoconstrictor Agents
  • ADAMTS13 Protein
  • ADAMTS13 protein, human